SCHEMBL3702948

SCHEMBL3702948

NC(=O)c1cccc(C(=O)c2c[nH]c3ncc(Cl)cc23)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 3/20 0.50
PLK4 O00444 2/20 0.50
AURKA O14965 2/20 0.50
ABL1 P00519 2/20 0.50
LCK P06239 2/20 0.50
FYN P06241 2/20 0.50
FES P07332 2/20 0.50
CSF1R P07333 2/20 0.50
LYN P07948 2/20 0.50
FGFR1 P11362 2/20 0.50
FLT1 P17948 2/20 0.50
KDR P35968 2/20 0.50
FLT3 P36888 2/20 0.50
FRK P42685 2/20 0.50
CLK2 P49760 2/20 0.50
BLK P51451 2/20 0.50
LIMK1 P53667 2/20 0.50
CSNK1G2 P78368 2/20 0.50
AURKB Q96GD4 2/20 0.50
SLK Q9H2G2 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298022 0.88 PAK1 (0.48) NEK2PLK4AURKAABL1LCK
SCHEMBL24011621 0.86 AAK1 (0.58) NEK2PLK4AURKAABL1LCK
SCHEMBL3710853 0.85 NEK2 (0.50) NEK2PLK4AURKAABL1LCK
SCHEMBL3705389 0.85 NEK2 (0.50) NEK2PLK4AURKAABL1LCK
SCHEMBL3506984 0.85 AXL (0.50) NEK2PLK4AURKAABL1LCK
SCHEMBL4570622 0.85 BRAF (0.49) NEK2PLK4AURKAABL1LCK
SCHEMBL3697175 0.83 BRAF (0.49) NEK2PLK4AURKAABL1LCK
SCHEMBL3711724 0.82 AAK1 (0.55) NEK2PLK4AURKAABL1LCK
SCHEMBL28489988 0.81 JAK2 (0.48) NEK2PLK4AURKAABL1LCK
SCHEMBL27795046 0.81 BRAF (0.54) NEK2PLK4AURKAABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF NEK2 949/4885PLK4 178/4885AURKA 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.